CGTLive’s Weekly Rewind – October 20, 2023


Review top news and interview highlights from the week ending October 20, 2023.

Welcome to CGTLive™’s Weekly Rewind! We’ve compiled 5 highlights from this week’s coverage of advances in gene and cell therapies, including FDA actions, notable research, and interviews with experts across the field.

1. Intellia’s CRISPR Therapy for ATTR-CM First to Enter Late-Stage Trials

Intellia Therapeutics plans to initiate the phase 3 trial of NTLA-2001 by the end of 2023.

2. Milind Desai, MD, MBA, on Addressing Unmet Needs in MYBPC3-associated Hypertrophic Cardiomyopathy

The director of the Center for Hypertrophic Cardiomyopathy at the Cleveland Clinic discussed TN-201, an investigational gene therapy for MYBPC3-associated HCM.

3. Canavan Gene Therapy Improves Developmental Measures Compared to Natural History

MSEL 5-mean domain, receptive language, and expressive language scores were significantly improved from baseline in treated participants.

4. David Rawlings, MD, on Research That Supports the Development of Engineered B-cell Therapies

The director of the Center for Immunity and Immunotherapies at Seattle Children's Research Institute discussed findings from several preclinical studies that could help bring engineered B-cell therapies to clinical trials.

5. bluebird's HGB-210 Trial Hopes to Support First SCD Gene Therapy Approval

Lovo-cel is currently being evaluated in the phase 3 HGB-210 study and has a PDUFA date of December 20, 2023.

Related Videos
Julie Kanter, MD
Mark Walters, MD
Sharon Hesterlee, PhD
Thomas Crawford, MD, on Helping Patients With SMA Left Behind by Gene Therapy
J. Andrew Livingston, MD
Pat Furlong, BSN, RN, on Future Areas of Research in DMD
© 2023 MJH Life Sciences

All rights reserved.